幼年皮肌炎的临床特征、肌肉活检评分、肌炎特异性抗体谱与结局
该研究回顾性分析了58例幼年皮肌炎(JDM)患者的临床特征、辅助检查、肌炎特异性抗体(MSA)、治疗反应及长期结局。结果显示皮肤病表现和肌无力是主要诊断要素,NXP2和TIF1γ抗体与严重病程相关,钙质沉着与发病年龄≤6岁、高肌肉活检评分及MDA5阳性相关,完全缓解率65.5%且复发率26.3%。
要点
- 皮肤病表现(91%)和肌无力(76%)是JDM关键诊断要素。
- NXP2和TIF1γ抗体提示严重病程,钙质沉着与MDA5阳性相关。
- 完全缓解率65.5%,中位24个月,复发率26.3%。
核心结论
- 整合临床特征、实验室检查和活检发现可能有助于预测JDM预后并指导治疗。
- 在本队列中,钙质沉着与发病年龄、MDA5自身抗体和肌肉活检评分相关。
研究设计与样本
- 回顾性队列研究,纳入近二十年来自三级转诊中心的58例JDM患者(35例女性,23例男性)。
- 平均发病年龄8.1±4.3岁,平均随访5.66±3.59年。
主要发现
- 皮肤病表现占91%,肌无力占76%;血清肌酸激酶升高占86%,肌电图异常23/25,肌肉MRI异常12/15,肌肉活检n=35。
- 46例检测MSA中34例(76%)自身抗体阳性,NXP2占21.7%,TIF1γ占17.4%,MDA5占8.7%,Mi-2占8.7%。
- 钙质沉着是最常见长期并发症(36%),与发病年龄≤6岁、较高肌肉活检评分和MDA5阳性相关。
- 65.5%患者达到完全缓解,中位时间24个月(IQR 11.8-42.5),复发率26.3%;NXP2阳性者43.9%复发,TIF1γ阳性者33.3%复发。
- 病程为单相型31%、多相型17.2%、慢性型51.8%,无死亡。
关键数值与推荐
- 初始治疗:糖皮质激素(100%)联合甲氨蝶呤(93%);生物制剂DMARDs用于22%的队列。
- TIF1γ和NXP2抗体提示严重病程;Ku抗体提示比既往研究更严重的病程。
临床怎么用
- 临床可结合MSA谱(如NXP2、TIF1γ、MDA5)和肌肉活检评分预测JDM预后并指导治疗强度。
- 对发病年龄≤6岁、MDA5阳性或高肌肉活检评分者应警惕钙质沉着风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood. OBJECTIVE: To analyze clinical features, paraclinical examinations, MSAs, treatment response and long-term outcome in a JDM cohort METHODS: 58 patients (35F, 23 M) from a tertiary referral center in the last two decades are included. RESULTS: Mean age at onset was 8.1 ± 4.3, with a mean follow-up period of 5.66±3.59 years. Dermatological manifestations (91%) and muscle weakness (76%) were the key diagnostic elements. Elevated serum creatine kinase levels (86%), electromyography (23/25), muscle MRI (12/15), and muscle biopsy (n = 35) were compatible with the diagnosis. Out of 46 patients tested, 34 (76%) had autoantibodies, with NXP2 (21.7%), followed by TIF1g (17.4%), MDA5 (8.7%), and Mi-2 (8.7%). Presence of TIF1g and NXP2 indicated a severe course; and Ku a much severe course compared to previous studies. Corticosteroids (100%) combined with methotrexate (93%) was the initial treatment. Biological disease modifying anti-rheumatic drugs (DMARDs) were used in 22% of the cohort. Calcinosis (36%) was the most common long-term complication, associated with disease onset ≤6 years, higher muscle biopsy scores and MDA5 positivity. Complete remission was achieved in 65.5% of the patients in a median 24 (IQR 11.8-42.5) months with a relapse rate of 26.3%. 43.9% of NXP2 and 33.3% of TIF-1 g positive patients had a relapse. Course was monophasic (31%), polyphasic (17.2%), chronic (51.8%) without mortality. CONCLUSION: Integration of clinical features with laboratory and biopsy findings may help to predict prognosis and guide treatment in JDM. In our cohort calcinosis was associated with age, MDA5 autoantibodies, and muscle biopsy scores.
引用
- Sag E, Demir S, Bilginer Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Semin Arthritis Rheum. 2020. PMID: 33360233. doi:10.1016/j.semarthrit.2020.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。